Qatar vs Sur: The number of people with susceptibility test result for rifampicin
Qatar
100
in 2021
Sur
97.1
in 2021
Qatar rank
2nd
Sur rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Qatar
- Sur
How they compare
Qatar currently reports 100 against 97.1 in Sur, a difference of 2.9.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Qatar ahead.
Qatar ranks 2nd and Sur ranks 2nd of 146 countries.
Across the 2 decades both report, Qatar averaged higher in 1 and Sur in 1.
Head to head by decade
| Decade | Qatar | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 83.79 | 86.78 | 2.98 | Sur |
| 2020s | 100 | 97.8 | 2.2 | Qatar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Qatar or Sur?
- Qatar, at 100 against 97.1 in Sur as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Qatar and Sur?
- 2.9, with Qatar ahead.
- How many years of comparable data are there for Qatar and Sur?
- 5 years are reported by both, from 2017 to 2021.
- How do Qatar and Sur rank globally for the number of people with susceptibility test result for rifampicin?
- Qatar ranks 2nd and Sur ranks 2nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.